A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)
NCT06966479
Recruiting
The primary purpose of this study is to evaluate the long-term safety and efficacy of verekitug (UPB-101) in participants who complete the VALIANT study (NCT06196879).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: Edward Jenner Research Group, LLC, Plantation, Florida +1 locations
Conditions: Severe Asthma
Register for Updates
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
NCT02074839
Recruiting
The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced hematologic malignancies that harbor an IDH1 mutation. The first portion of the study is a dose escalation phase where cohorts of patients will receive ascending oral doses of AG-120 to determine maximum tolerated dose (MTD) and/or the recommended Phase II dose. The second portion of the study is a dose expansion phase where four cohorts of pati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +29 locations
Conditions: Relapsed or Refractory Acute Myeloid Leukemia (AML), Untreated AML, Other IDH1-mutated Positive Hematologic Malignancies, Myelodysplastic Syndromes
Register for Updates
An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer and Other Malignancies of the Head and Neck Undergoing Radiation Therapy and/or Systemic Therapy
NCT04589624
Recruiting
This trial investigates whether hyperpolarized magnetic resonance imaging (hpMRI) can predict treatment response in patients with thyroid cancer and other malignancies of the head and neck undergoing radiation therapy and/or receiving systemic therapy before surgery. An hpMRI is like a standard MRI but involves the use of an imaging contrast agent called hyperpolarized 13-C-pyruvate. Diagnostic procedures, such as hpMRI, may predict a patient's response to treatment and may help plan the best tr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Thyroid Gland Carcinoma
Register for Updates
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations
NCT05048797
Recruiting
DESTINY-Lung04 will investigate the efficacy and safety of Trastuzumab Deruxtecan (T-DXd) versus Standard of Care (SoC) as first-line treatment of Non-Small Cell Lung Cancer (NSCLC) with HER2 Exon 19 or 20 mutations
Gender:
ALL
Ages:
Between 18 years and 123 years
Trial Updated:
06/06/2025
Locations: Research Site, Anchorage, Alaska +162 locations
Conditions: Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Register for Updates
Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
NCT05531786
Recruiting
Background: Chronic graft-versus-host disease (cGVHD) is an immune system disorder that can occur in people who have had a stem cell transplant. cGVHD can affect multiple organs and increase risk of disability and death. New treatments are needed to treat cGVHD after stem cell transplant. Objective: To test a drug (pacritinib) in people with moderate or severe cGVHD that has not responded to previous treatment. Eligibility: People aged 18 years and older with moderate or severe cGVHD that h... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Graft vs Host Disease
Register for Updates
Novel Outreach Methods to Increase Enrollment to Early Phase Clinical Trials
NCT05886764
Recruiting
This trial will study different outreach methods to assess impact on enrollment of underrepresented minorities (specifically African Americans) to early phase cancer clinical treatment trials. Both patients and providers (those seeing enrolled patients) will be enrolled and receive the study interventions or no intervention (control arm).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois
Conditions: Cancer, Malignancy, Malignant Neoplasm
Register for Updates
A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old
NCT06064929
Recruiting
In this study, researchers will learn more about the use of felzartamab in people with active lupus nephritis, also known as LN. In people with LN, antibodies build up in the glomeruli of the kidneys. Antibodies are proteins in the blood used by the immune system to fight infection. Glomeruli are small filters that remove waste and extra fluid from the blood. This buildup leads to inflammation and damage to the kidneys. Kidney damage can lead to too much protein and blood leaking into the urine... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/06/2025
Locations: Centricity Research - Phoenix, Mesa, Arizona +27 locations
Conditions: Lupus Nephritis
Register for Updates
A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
NCT06365853
Recruiting
The purpose of this study is to evaluate the incidence rate and severity of prespecified mirvetuximab soravtansine (MIRV)-related ocular treatment-emergent adverse events (TEAEs) and assess prophylaxis strategies in all participants (symptomatic and asymptomatic) undergoing prospective ophthalmic evaluation with recurrent ovarian cancer (participants with either platinum-sensitive ovarian cancer \[PSOC\] or platinum-resistant ovarian cancer \[PROC\]) with high folate receptor alpha (FRα) express... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: University of California Los Angeles /ID# 269339, Los Angeles, California +39 locations
Conditions: Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive
Register for Updates
PhI Pilot Study Pafolacianine Inject for Intraoperative Imaging on Outcomes of GI Cancer Peritoneal Carcinomatosis
NCT06511037
Recruiting
This is a pilot, single-arm, open label study to evaluate the ability of CYTALUX™ (pafolacianine) to help identify cancerous lesions in subjects with gastrointestinal cancers and peritoneal carcinomatosis during cytoreductive surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California
Conditions: Gastrointestinal Cancer, Peritoneal Carcinomatosis
Register for Updates
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
NCT06665256
Recruiting
A Phase 2, randomized, open-label, controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe refractory idiopathic inflammatory myopathies (IIM)
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/06/2025
Locations: Northwestern University, Chicago, Illinois +24 locations
Conditions: Idiopathic Inflammatory Myopathies
Register for Updates
Clinical Trial Evaluating the Safety and Efficacy of Nucleus Pulposus Allograft in Participants With Degenerative Disc Disease
NCT06778447
Recruiting
VIA Disc NP is a non-surgical intervention intended to supplement nucleus pulposus tissue in degenerated intervertebral discs. This is a randomized, sham-controlled, multi-center, double-blind clinical trial with an open label roll-in period of one participant per site in which participants with lumbar discogenic pain associated with DDD will receive one VIA Disc NP treatment to each affected level (up to 2 levels). Participants enrolled after the roll-in stage will be randomized on a 2:1 basis... Read More
Gender:
ALL
Ages:
Between 22 years and 85 years
Trial Updated:
06/06/2025
Locations: Premier Spine and Pain Institute, Thornton, Colorado +1 locations
Conditions: Degenerative Disc Disease, Disc Degeneration, Lumbar Discogenic Pain
Register for Updates
A Phase 1 Trial of Intranasal Mumps Virus Vaccines in Healthy Adults
NCT06967181
Recruiting
The purpose of this trial is to evaluate the safety and immunogenicity of CVM150 and CVM26. The trial will enroll up to 60 healthy participants.
Gender:
ALL
Ages:
Between 18 years and 29 years
Trial Updated:
06/06/2025
Locations: University Of Rochester Medical Center, Rochester, New York +2 locations
Conditions: Mumps
Register for Updates